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Abstract
The malaria vaccine candidate RTS,S/AS01 (GSK Vaccines) induces high IgG titers against the circumsporozoite protein (CSP) of P. falciparum. In human vaccine recipients circulating anti-CSP antibody titres are associated with 
protection against infection but appear not to be the ultimate correlate of protection. However, in a humanized mouse model of malaria infection prophylactic administration of a human monoclonal antibody (MAL1C) directed 
against the CSP repeat region conveyed full protection in a dose-dependent manner [1] suggesting that antibodies alone are able to prevent P. falciparum infection when present in high enough concentrations. A competition ELISA 
was developed to measure the presence of MAL1C-like antibodies in polyclonal sera from RTS,S vaccine recipients and study their possible contribution to protection against infection. Serum samples were taken at different time 
points from participants of 2 RTS,S/AS01 vaccine studies. Vaccine-induced protection status of the study participants was determined based on the outcome of experimental challenge with infectious mosquito bites after vaccination.
Development of the MAL1C-type inhibition assay.
Optimal dilutions of B-MAL1C and streptavidin-HRP 
were defined using a checkerboard titration 
experiment (A). At a 1/16,000 dilution of streptavidin-
HRP a sigmoidal curve was observed; this dilution was 
used for further experiments. B-MAL1C dilutions in 
the range between the maximal absorbance  (plateau 
observed at 1/50,000) and half max (max/2 observed 
at 1/400,000) were explored in an inhibition set up
using defined sera with high and low antibody content in R32LR ELISA assay (B) and the three monoclonal 
antibodies, MAL1C, MAL2B and MAL3A (C). The data shown in panels B and C were obtained with the highest 
serum concentrations (starting dilution 1/5) and with mAb concentrations of 5 µg/mL.
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Interactions between the three mAbs (MAL1C, MAL2A, and MAL3B) and the CSP-derived peptides as 
measured by SPR. The data for the mAb:CSP-peptide interaction were measured in the format of a kinetic 
titration [2], with mAb as the ligand (i.e., coated onto the sensor surface) and either (NANP)6 (A.) and R32LR (B.) 
as the analyte. In both panels,  the top graphs display the sensorgrams (black traces) and the fit to the data with 
a 1:1 Langmuir binding model (red traces). The residuals of the fit are shown in the bottom graph. The (apparent) 
affinity constants for the interactions and the chi2 of the fit are also shown for convenience.
Methods
A competition ELISA was developed to measure the presence of MAL1C-like antibodies in polyclonal sera from
RTS,S/AS01 vaccine recipients and study their possible contribution to protection against infection. The assay relies
on the competition of MAL1C-like antibodies present in polyclonal vaccine-induced sera with biotinylated
monoclonal antibody MAL1C for binding sites on the capture antigen consisting of the recombinant protein
encompassing 32 NANP repeats of CSP (R32LR). Serum samples were taken at different time points from
participants of 2 RTS,S/AS01 vaccine studies. Vaccine-induced protection status of the study participants was 
determined based on the outcome of experimental challenge with infectious mosquito bites after vaccination.
Results
Correlation between R32LR ELISA and MAL1C-type inhibition assay. Sera from participants from 
Study A and Study B taken after the second and third vaccine doses (immediately prior to mosquito 
bite challenge) were analyzed with the standard R32LR ELISA [3] and the MAL1C-type inhibition ELISA. 
A Pearson product-moment correlation coefficient was computed to assess the relationship between 
the antibody concentrations measured in both assays. In both studies there was a strong, positive 
correlation between the results obtained in the two assays. 
Study A Study B
r = 0.705
P (two-tailed) = < 0,0001
r = 0.546
P (two-tailed) = < 0,0001
SStudy A Study B
Correlation between protection from infection and antibody content, measured with both R32LR 
ELISA and MAL1C-type inhibition assay. Antibody concentrations in the sera obtained immediately 
before challenge with infected mosquito’s from participants at the A (n=46) and B (n=46) studies were 
measured with the R32LR ELISA and MAL1C-type inhibition assay. We ran a Mann-Whitney's U test to 
evaluate the difference in the antibody concentrations in protected and non-protected vaccine 
recipients. In study B no significant differences were observed irrespective of the assay used, whereas 
in study A the difference was significant.
Median protected = 67,75
Median non protected = 36,90
Mann-Whitney U = 146,0
P (two-tailed) = 0,0087
Median protected = 116,9
Median non protected = 50,20
Mann-Whitney U = 120,0
P (two-tailed) = 0,0012
Median protected = 106,20
Median non protected = 67,09
Mann-Whitney U = 127,0
P (two-tailed) = 0,1600
Median protected = 58,55
Median non protected = 69,85
Mann-Whitney U = 179,0
P (two-tailed) = 0,9846
Conclusions
A competition ELISA, developed to measure polyclonal MAL1C-like antibodies in sera from RTS,S vaccine 
recipients, was robust and specific, but did not show any new correlates of protection. Further work is 
needed to evaluate the role of other factors in protection against malaria.
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